| Primary | ICU-Free Days | 28-day hospital mortality-adjusted ICU length of stay. | | Posted | | Median | Inter-Quartile Range | Days | | Study day 28 | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG00020(1.0 to 24.2)
- OG00119.4(7.1 to 23.9)
|
|
| |
| Secondary | 90-day Hospital Mortality | In order to enable direct comparisons between data gathered in HALF-PINT and the prior adult NICE-SUGAR trial, we will collect data on 90-day hospital mortality. | | Posted | | Count of Participants | | Participants | | 90 days after randomization | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | 28-day Hospital Mortality | We will collect data on 28-day hospital mortality. | | Posted | | Count of Participants | | Participants | | 28 days after randomization | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Accumulation of Multiple Organ Dysfunction Syndrome (MODS) | Accumulation of MODS during the 28 days following randomization will be measured. MODS is defined as the concurrent dysfunction of two or more organ systems (e.g., acute lung injury and renal failure). The clinical relevance of MODS as a surrogate outcome measure is well recognized in the intensive care community, and there is a clear relationship between the number of dysfunctional organ systems and the risk of death in critically ill children. | | Posted | | Count of Participants | | Participants | | 28 days after randomization | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Ventilator-Free Days | Ventilator-free days during the 28 days following randomization encompasses both reduction in the duration of ventilation and improvement in mortality. The end of the subject's duration of ventilation is defined as the date/time of extubation for subjects who are intubated, or the date/time of the discontinuation of mechanical ventilation for subjects with tracheostomy. | | Posted | | Median | Inter-Quartile Range | Days | | 28 days following randomization | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Developmental Neurobehavioral Outcomes: VABS-II Composite | Reliable, reproducible measures of adaptive functioning, behavior and quality of life will be used to determine outcomes at baseline (CBCL, PedsQL) and at one year after ICU discharge (Vineland-II, CBCL, PedsQL). The goal of baseline data collection is to assess pre-ICU health and quality of life. The results of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) are reported. Scores range from 20-160, with higher scores being better. | | Posted | | Mean | Standard Deviation | Score on a scale | | One year after ICU course | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Participants With Device-Related or Non-Device Related Nosocomial Infection | We will use Centers for Disease Control's (CDC) most recently published definitions for the following nosocomial infections attributable to the ICU stay: total bloodstream infections including Central Venous Line (CVL)-associated bloodstream infections (BSI), respiratory tract infections including ventilator-associated pneumonias, urinary tract infections, and wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. | | Posted | | Count of Participants | | Participants | | Up to 48 hours after ICU discharge | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Incidence of Catheter-Associated Bloodstream Infection | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: Central Venous Line (CVL)-associated bloodstream infections (BSI) that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days. | | Posted | | Number | | Infections/1000 CVC days | | Up to 48 hours after ICU discharge | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Incidence of Catheter-Associated Urinary Tract Infection | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: urinary tract infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days. | | Posted | | Number | | Infections/1000 bladder catheter days | | Up to 48 hours after ICU discharge | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Incidence of Ventilator-Associated Pneumonia | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: respiratory tract infections including ventilator-associated pneumonias that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days. | | Posted | | Number | | Infections/1000 ventilator days | | Up to 48 hours after ICU discharge | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Incidence of Wound Infection Incidence of Wound Infection | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This non-device-related infection will be counted per 1,000 ICU days. | | Posted | | Number | | Infections/1000 ICU days | | Up to 48 hours after ICU discharge | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | Hypoglycemia will be tracked and reported according to three ranges: severe (<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia <2.5 mmol/L will also be tracked. | | Posted | | Count of Participants | | Participants | | Participants will be followed for the duration of ICU stay, an expected average of 8 days | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | Hypoglycemia will be tracked and reported according to three ranges: severe (<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia <2.5 mmol/L will also be tracked. | | Posted | | Count of Participants | | Participants | | Participants will be followed for the duration of ICU stay, an expected average of 8 days | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | Hypoglycemia will be tracked and reported according to three ranges: severe (<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia <2.5 mmol/L will also be tracked. | | Posted | | Count of Participants | | Participants | | Participants will be followed for the duration of ICU stay, an expected average of 8 days | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | Hypoglycemia will be tracked and reported according to three ranges: severe (<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia <2.5 mmol/L will also be tracked. | | Posted | | Count of Participants | | Participants | | Participants will be followed for the duration of ICU stay, an expected average of 8 days | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Participants With Hypokalemia (<2.5 mmol/L) | Hypoglycemia will be tracked and reported according to three ranges: severe (<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia <2.5 mmol/L will also be tracked. | | Posted | | Count of Participants | | Participants | | Participants will be followed for the duration of ICU stay, an expected average of 8 days | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument | The workload burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient during one shift. Using the SWAT (Subjective Workload Assessment Technique) instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The SWAT has been used to study the effect of workload in the fields of nursing, pharmacy and medicine. It measures the following burdens: cognitive (mental effort or concentration required for complexity of task), time (amount of spare time, interruptions, overlapping tasks) and psychological stress associated with work that impacts performance. The SWAT uses a ranking system to weight perceived workload which results in an overall score ranging from 0-100, where higher scores indicate higher perceived workload. | | Posted | | Median | Inter-Quartile Range | score on a scale | | One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.). | | | | ID | Title | Description |
|---|
| OG000 | Perceived Nursing Workload: Caring for TGC Group 1 Patients | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. The nurses surveyed were caring for a patient in this treatment arm. |
|
| Secondary | Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument | The cognitive burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient on TGC. Using the NASA-TLX instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The instrument uses a ranking system to weight perceived workload which results in an overall sore ranging from 0-100, where higher scores indicate higher perceived workload. It obtains overall perception of workload related to stressful tasks and includes 6 dimensions (cognitive demand, physical demand, time pressure, performance, effort, and frustration. | | Posted | | Median | Inter-Quartile Range | score on a scale | | One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.). | | | | ID | Title | Description |
|---|
| OG000 | Perceived Nursing Workload: Caring for TGC Group 1 Patients | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. The nurses surveyed were caring for a patient in this treatment arm. | | OG001 | Perceived Nursing Workload: Caring for TGC Group 2 Patients |
|
| Secondary | Insulin Algorithm Performance: Time to the Target Range | Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will minimize time to glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high. | | Posted | | Median | Inter-Quartile Range | Hours | | Until study discharge, up to 28 days following randomization | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Insulin Algorithm Performance: Time in the Target Range | Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will maximize time spent in the glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high. | | Posted | | Median | Inter-Quartile Range | Percentage of time | | Until study discharge, up to 28 days following randomization | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |
| Secondary | Insulin Algorithm Performance: Time-Weighted Glucose Average | Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high. | | Posted | | Median | Inter-Quartile Range | mg/dL | | Until study discharge, up to 28 days following randomization | | | | ID | Title | Description |
|---|
| OG000 | Tight Glycemic Control 1 (TGC-1) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | | OG001 | Tight Glycemic Control 2 (TGC-2) | Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm. Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL |
| |